Dr. Javad Nazarian is an internationally renowned researcher whose work has reshaped the landscape of pediatric brain tumor science. As a Scientific Chair of CBTN, he helps guide the network’s global research collaborations, with a special focus on rare and hard-to-treat diseases such as diffuse midline gliomas. His leadership spans continents and institutions, combining molecular biology, data science, and patient advocacy to drive meaningful progress. Through his roles with DMG-ACT, the DIPG Registry, and the University of Zurich, Dr. Nazarian ensures that CBTN remains a driving force for innovation and a trusted partner in the worldwide effort to cure childhood brain cancer.
